Eyeworld

EW NEWS & OPINION 16 ary IOL insertion in aphakic patients who are contact lens intolerant (Figure 7). EW References 1. McCannel MA. A retrievable suture idea for anterior uveal problems. Ophthalmic Surg 1976; 7(2):98-103. 2. Stark WJ, Michels RG, Bruner WE. Manage- ment of posteriorly dislocated intraocular lenses. Ophthalmic Surg 1980; 11:495-497. 3. Stark WJ, Goodman G, Goodman D, Gottsch J. Posterior chamber intraocular lens implan- tation in the absence of posterior capsular support. Ophthalmic Surg 1988; 19:240-243. 4. Stutzman RD, Stark WJ. Surgical technique for suture fixation of an acrylic intraocular lens in the absence of capsule support. J Cataract Refract Surg 2003; 29:1658-1662. Editors' note: Drs. Daoud and Stark have no financial interests related to this article. Contact information Daoud: ydaoud1@jhmi.edu Stark: wstark1@jhmi.edu December 2011 DUOVISC® Viscoelastic System is designed to give two viscoelastic materials with different physico-chemical properties that can be used differently and/or sequen- tially to perform specific tasks during a cataract procedure. DUOVISC® Viscoelastic System consists of VISCOAT® Ophthalmic Viscosurgical Device and PROVISC® Ophthalmic Viscosurgical Device. CAUTION: Federal law restricts this device to sale by or on the order of a physician. Viscoat® (Sodium Chondroitin Sulfate – Sodium Hyaluronate) Ophthalmic Viscosurgical Device Indications: Viscoat is indicated for use as an ophthalmic surgical aid in anterior segment procedures including cataract extraction and intraocular lens (IOL) implan- tation. Viscoat maintains a deep anterior chamber during anterior segment surgeries, enhances visualization during the surgical procedure, and protects the corneal endothelium and other ocular tissues. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. Warnings: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury. Precautions: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material. Adverse Reactions: Viscoat has been extremely well tolerated in human and animal studies. A transient rise in intraocular pressure in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise. It is therefore recommended that Viscoat be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber. ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions. ProVisc® (Sodium Hyaluronate) Ophthalmic Viscosurgical Device Indications: ProVisc is indicated for use as an ophthalmic surgical aid in the anterior segment during cataract extraction and intraocular lens (IOL) implantation. Ophthalmic viscoelastics serve to maintain a deep anterior chamber during anterior segment surgery allowing reduced trauma to the corneal endothelium and sur- rounding ocular tissues. They help push back the vitreous face and prevent formation of a flat chamber during surgery. Precautions: Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should be carefully monitored and appro- priate therapy instituted if significant increases should occur. It is recommended that ProVisc® be removed by irrigation and/or aspiration at the close of surgery. Do not overfill anterior chamber. Although sodium hyaluronate is a highly purified biological polymer, the physician should be aware of the potential allergic risks inherent in the use of any biological material; care should be used in patients with hypersensitivity to any components in this material. Cannula assembly instructions should be followed to prevent patient injury. Adverse Reactions: Postoperative inflammatory reactions such as hypopyon and iritis have been reported with the use of ophthalmic viscoelastics, as well as inci- dents of corneal edema, corneal decompensation, and a transient rise in intraocular pressure. ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions. © 2011 Novartis 11/11 VIS11584JAD-PI DisCoVisc® Ophthalmic Viscosurgical Device (Sodium Chondroitin Sulfate – Sodium Hyaluronate). Description: DisCoVisc® Ophthalmic Viscosurgical Device has an intermediate cohesive/dispersive index (CDI) and can best be described as the first viscous dis- persive viscoelastic and is optimized for the entire surgical procedure. Indications: DisCoVisc® Ophthalmic Viscosurgical Device is indicated for use during surgery in the anterior segment of the eye. It is designed to create and maintain space, to protect the corneal endothelium and other intraocular tissues and to manipulate tissues during surgery. It may also be used to coat intraocular lenses and instruments during cataract extraction and IOL insertion. Warnings: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury. Precautions: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material. Adverse Reactions: DisCoVisc® Ophthalmic Viscosurgical Device was very well tolerated in nonclinical and clinical studies. A transient rise in intraocular pressure in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise. It is therefore recom- mended that DisCoVisc be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber. ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions. CAUTION: FEDERAL (USA) LAW RESTRICTS THIS DEVICE TO THE SALE BY OR ON THE ORDER OF A PHYSICIAN. U.S. Patent Nos. 5,273,056; 5,876,379 and 6,051,560. 77117 VIS11584JAD_PI EW.indd 1 11/7/11 3:18 PM Iris-fixated continued from page 14 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Source: Yassine Daoud, M.D., and Walter J. Stark, M.D.

• Cover